RBM5 reduces small cell lung cancer growth, increases cisplatin sensitivity and regulates key transformation-associated pathways
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer, with almost 95% of patients succumbing to the disease. Although RBM5, a tumor suppressor gene, is downregulated in the majority of lung cancers, its role in SCLC is unknown. Using the GLC20 SCLC cell line, which has a homozygo...
Main Authors: | Julie J. Loiselle, Justin G. Roy, Leslie C. Sutherland |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-11-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844016315808 |
Similar Items
-
Downregulation of RBM17 enhances cisplatin sensitivity and inhibits cell invasion in human hypopharyngeal cancer cells
by: Wang Xiaolin, et al.
Published: (2023-03-01) -
Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues
by: Liang Hong, et al.
Published: (2012-04-01) -
Correction: EPS8 Inhibition Increases Cisplatin Sensitivity in Lung Cancer Cells
Published: (2014-01-01) -
RBM - rice bran Malaysia
by: Ismail, Maznah
Published: (2005) -
Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD)
by: Liusheng Wu, et al.
Published: (2023-06-01)